RxDoctor Payments Data

Moinakhtar Lala, MD

Cardiovascular Disease · Reseda, CANPI 1396907119

Payments from drug & device makers

$248,586in general payments, 2019–2025

Across 2,194 payments — averaging $113.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$114K
  • Angiodynamics, Inc.$69K
  • Cardiovascular Systems Inc.$17K
  • Boston Scientific$5K
  • Abbott$5K
  • Bard Peripheral Vascular, Inc.$4K
  • plus $35K from 54 others

What the payments were for

  • Consulting fees$125,42558%
  • Speaking & faculty fees$24,12511%
  • Travel & lodging$6,4603%
  • Food & beverage$61,36328%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Philips North America LLC65$114,044
Angiodynamics, Inc.237$68,519
Cardiovascular Systems Inc.113$17,072
Boston Scientific125$5,060
Abbott121$4,956
Bard Peripheral Vascular, Inc.77$3,632
Abiomed54$3,471
Amgen(2 entities)112$2,670
Medtronic(2 entities)72$2,034
Novartis174$1,979
Inari Medical, Inc.15$1,834
Shockwave Medical, Inc58$1,747
Cook Medical LLC91$1,669
Johnson & Johnson91$1,541
Boehringer Ingelheim64$1,444
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)81$1,302
Lilly USA, LLC76$1,255
Amarin Pharma, Inc.54$1,168
AstraZeneca57$1,125
E.r. Squibb & Sons, L.L.C.64$956
Merck34$815
Tactile Systems Technology Inc29$806
BD16$642
Pfizer27$522
Novo Nordisk26$520
Biotronik Inc.19$497
Terumo Medical Corporation8$479
Bayer23$448
Koya Medical, Inc.2$418
Cvrx, Inc.3$345
Bardy Diagnostics, Inc.8$324
Lexicon Pharmaceuticals, Inc.21$318
Esperion Therapeutics, Inc.16$312
Daiichi Sankyo Inc.14$296
Alnylam Pharmaceuticals Inc.14$296
Veryan Medical Incorporated9$283
Actelion Pharmaceuticals US, Inc.12$283
Edwards Lifesciences7$275
Asahi Intecc USA, Inc.3$263
Baxter Healthcare9$258
Heartflow, Inc.6$247
Kestra Medical Technology Services, Inc.10$232
Bridgebio Pharma, Inc.7$212
Biosense Webster, Inc.3$208
Surmodics, Inc.7$195
Takeda Pharmaceuticals U.S.A., Inc.9$173
Kiniksa Pharmaceuticals International, PLC6$168
Stryker2$144
Reflow Medical Inc4$140
Curonix LLC1$115
Regeneron Healthcare Solutions, Inc.4$108
Sanofi-aventis U.S. LLC5$92
Cordis US CORP.4$91
Kiniksa Pharmaceuticals, Ltd.3$82
Integra Lifesciences Corporation3$77
Irhythm Technologies, Inc.2$56
Impulse Dynamics (USA) Inc.2$51
Medline Industries LP2$41
Resmed Corp1$38
Kowa Pharmaceuticals America, Inc.1$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$248,586 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$6,374,525
Medicare patients
1,839
Services billed
27,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban262$214,193
XareltoRivaroxaban225$173,874
MounjaroTirzepatide87$107,792
Repatha SureclickEvolocumab106$82,699
TrulicityDulaglutide35$51,367
EntrestoSacubitril/Valsartan30$35,796
BrilintaTicagrelor49$28,234
OzempicSemaglutide28$26,616
Praluent PenAlirocumab25$19,898
VerquvoVericiguat14$9,427
ClopidogrelClopidogrel Bisulfate818$6,646
Icosapent Ethyl11$1,610
Rosuvastatin Calcium103$1,361
Metoprolol Succinate112$946
Atorvastatin Calcium109$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$522$214,193262 claims
Johnson & JohnsonXarelto$1,541$173,874225 claims
Lilly USA, LLCMounjaro, Trulicity$1,255$159,159122 claims
NovartisEntresto$1,979$35,79630 claims
AstraZenecaBrilinta$1,125$28,23449 claims
Novo NordiskOzempic$520$26,61628 claims
MerckVerquvo$815$9,42714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →